Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-03-05 00:00:00 ET · period of report 2026-03-03 · accession 0001104659-26-023943 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-05 | 2026-03-03 | LGND | Sabba Stephen L | Dir | M - OptEx | $69.51 | +2,034 | 35.8K | +6% | +$141.4K |
| D | 2026-03-05 | 2026-03-03 | LGND | Sabba Stephen L | Dir | S - Sale+OE | $201.50 | -2,034 | 33.8K | -6% | -$409.9K |
| D | 2026-03-05 | 2026-03-03 | LGND | Sabba Stephen L | Dir | M - OptEx | $0.00 | -2,034 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-03 | M | A | 2,034 | $69.51 | 35,827 | D | — | — | (F1) These securities, as represented in Column 5, includes the grant of 1,209 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 6, 2025, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 10 June 2025, which was filed to reflect the 2025 Meeting grant. |
| 2 | Common | Common Stock | 2026-03-03 | S | D | 2,034 | $201.50 | 33,793 | D | — | — | (F1) These securities, as represented in Column 5, includes the grant of 1,209 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 6, 2025, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 10 June 2025, which was filed to reflect the 2025 Meeting grant. |
| 3 | Derivative | Non- Qualified Stock Option (right to buy) | 2026-03-03 | M | D | 2,034 | $0.00 | 0 | D | $69.51 · — to 2026-05-23 | 2,034 Common Stock | (F2) These securities, as represented in Column 5, were acquired by a grant of 2,329 shares approved by the Board of Directors of the Company at the 2016 Meeting, as previously reported on the Reporting Person's Form 4, dated 25 May 2016. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,034 shares and the exercise price adjusted to $69.51 pursuant to the OmniAb Inc. separation from the Company. |